title: [Experiences with DHPG (ganciclovir)--treatment of cytomegalovirus retinitis in AIDS].
abstract: Nine patients with unilateral cytomegalovirus (CMV) retinitis were treated with intravenous infusions of the new virustatic drug DHPG (Ganciclovir). The induction dose was 10 mg/kg body weight per day (2-5 weeks). In six cases, a maintenance dose was given thereafter of 5 mg/kg body weight per day. After the induction dose, five patients had visual improvement and satisfactory cicatrization. In one patient, PVR (proliferative vitreous reaction) developed with total tractional retinal detachment. More ocular complications were seen while on longterm therapy: relapses during discontinuation because of leukopenia (three times in two patients), breakthrough (= relapse during maintenance therapy) (one case), serous retinal detachment (one case), and optic atrophy (two cases). The complications caused blindness in two further patients. Only one patient has tolerated maintenance therapy for 22 weeks without having any complications. One patient wanted to have therapy suspended and has remained free of relapse for 28 weeks while on cytostatic therapy. The eyes of two deceased patients were examined histopathologically, immunhistochemically, and ultrastructurally and the findings compared with those of an untreated case. Given at an early stage and without discontinuation, DHPG is an effective means of preventing or delaying blindness caused by cytomegalovirus retinitis in AIDS patients. The directives for an optimal dosage are subject to further prospective randomized clinical studies.
authors.forename: E M
authors.initials: EM
authors.lastname: Fabricius
authors.forename: E
authors.initials: E
authors.lastname: Holzer
authors.forename: F
authors.initials: F
authors.lastname: Prantl
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000212:Acyclovir / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000998:Antiviral Agents / Q000008:administration & dosage*; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy*; D015774:Ganciclovir; D006801:Humans; D007267:Injections; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D012173:Retinitis / Q000150:complications / Q000188:drug therapy*; D014822:Vitreous Body / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D015774:Ganciclovir; D000212:Acyclovir
vernacular_title: Erfahrungen mit DHPG (Ganciclovir)--Behandlung der Cytomegalievirus-Retinitis bei AIDS.